eli lilly tirzepatide trial Lilly's Zepbound tops Wegovy for weight loss in head-to-head Eli Lilly lifts 2026 revenue

108 The strongest evidence that demonstrates GLP-1s ability to directly inhibit glucagon secretion comes from the observation that the ability of T1D patients to secrete glucagon is suppressed after GLP-1 infusion and glycaemic control is improved

The study showed that 37.5% of the women noticed skin brightening after they had completed 12 infusions over six weeks

This research suggests that with new anti-obesity medications like tirzepatide, the focus of lifestyle changes may shift from simply losing weight through calorie restriction to helping people adopt healthier lifestyles that improve body composition and overall well-being

Psychiatry J (2014) 2014:136158.10.1155/2014/136158 9 RossignolDAFryeRE

Breakthrough Prize recognizes Daniel Drucker for work leading to diabetes, anti-obesity drugs Daniel Drucker , the Canadian scientist renowned for discoveries that sparked the advent of Ozempic and other GLP-1 medicines for diabetes and obesity, has added yet another accolade to his growing collection: the 2025 Breakthrough Prize in Life Sciences